Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 3015-3022

  Tong, Wei Gang ^a   Chen, Rong ^a   Plunkett, William ^a   Siegel, David ^a   Sinha, Rajni ^a   Harvey, R Donald ^a   Badros, Ashraf Z ^a   Popplewell, Leslie ^a   Coutre, Steven ^a   Fox, Judith A ^a   Mahadocon, Kristi ^a   Chen, Tianling ^a   Kegley, Peggy ^a   Hoch, Ute ^a   Wierda, William G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PROTEIN MCL 1; X LINKED INHIBITOR OF APOPTOSIS; CDK2 PROTEIN, HUMAN; CDK9 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE; N (5 (((5 (1,1 DIMETHYLETHYL) 2 OXAZOLYL)METHYL)THIO) 2 THIAZOLYL) 4 PIPERIDINECARBOXAMIDE; N-(5-(((5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL)METHYL)THIO)-2-THIAZOLYL)-4-PIPERIDINECARBOXAMIDE; OXAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; TUMOR MARKER;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACTEREMIA; BONE MARROW SUPPRESSION; CAPILLARY LEAK SYNDROME; CELLULITIS; CHOLECYSTITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; HYPOXIA; LOADING DRUG DOSE; LUNG INFILTRATE; MALE; MAXIMUM PERMISSIBLE DOSE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OTITIS MEDIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SPLEEN SIZE; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR LYSIS SYNDROME; TUMOR VOLUME; VOMITING; BLOOD; COHORT ANALYSIS; DRUG ANTAGONISM; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COHORT STUDIES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 9; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; OXAZOLES; SURVIVAL RATE; THIAZOLES; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954611291     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.1347     Document Type: Article

References (31)

1. Cheson BD: Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag 3:855-870, 2007
2. Soundararajan S, Chen W, Spicer EK, et al: The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 68:2358-2365, 2008 (Pubitemid 351521810)
3. Del Gaizo Moore V, Brown JR, Certo M, et al: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112-121, 2007 (Pubitemid 46048458)
4. Nguyen M, Marcellus RC, Roulston A, et al: Small molecule Obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 104:19512-19517, 2007
5. Balakrishnan K, Wierda WG, Keating MJ, et al: Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112:1971-1980, 2008
6. Mohammad RM, Goustin AS, Aboukameel A, et al: Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 13:2226-2235, 2007 (Pubitemid 46649892)
7. Blagden S, de Bono J: Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 6:325-335, 2005 (Pubitemid 40667798)
8. Senderowicz AM: Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 15:1-9, 2001
9. Chen R, Keating MJ, Gandhi V, et al: Transcription inhibition by flavopiridol: Mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513-2519, 2005 (Pubitemid 41510827)
10. Chen R, Wierda WG, Chubb S, et al: Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113:4637-4645, 2009
11. Hahntow IN, Schneller F, Oelsner M, et al: Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18:747-755, 2004 (Pubitemid 38500193)
12. Schwartz GK, Shah MA: Targeting the cell cycle: A new approach to cancer therapy. J Clin Oncol 23:9408-9421, 2005
13. Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783, 2006
14. Senderowicz AM: Small-molecule cyclin-dependent kinase modulators. Oncogene 22:6609-6620, 2003
15. Hwang HC, Clurman BE: Cyclin E in normal and neoplastic cell cycles. Oncogene 24:2776-2786, 2005 (Pubitemid 40638089)
16. Gojo I, Zhang B, Fenton RG: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527-3538, 2002 (Pubitemid 35340731)
17. Byrd JC, Shinn C, Waselenko JK, et al: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92:3804-3816, 1998 (Pubitemid 28525207)
18. Byrd JC, Peterson BL, Gabrilove J, et al: Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 11:4176-4181, 2005 (Pubitemid 40791583)
19. Flinn IW, Byrd JC, Bartlett N, et al: Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 29:1253-1257, 2005 (Pubitemid 41297636)
20. Tan AR, Headlee D, Messmann R, et al: Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20:4074-4082, 2002
21. Rudek MA, Bauer KS Jr, Lush RM III, et al: Clinical pharmacology of flavopiridol following a 72- hour continuous infusion. Ann Pharmacother 37:1369-1374, 2003 (Pubitemid 37205488)
22. Byrd JC, Lin TS, Dalton JT, et al: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404, 2007 (Pubitemid 46105932)
23. Phelps MA, Lin TS, Johnson AJ, et al: Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113:2637-2645, 2009
24. Conroy A, Stockett DE, Walker D, et al: SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 64:723-732, 2009
25. Reddy M, Arbitrario JP, Jones J, et al: SNS- 032 has potent antitumor activity in vivo against human leukemia and multiple myeloma xenografts. AACR Meeting Abstracts, 2007 (abstr A258)
26. Heath EI, Bible K, Martell RE, et al: A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26:59-65, 2008
27. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
28. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998 (Pubitemid 28435189)
29. Ali MA, Choy H, Habib AA, et al: SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 9:370-381, 2007 (Pubitemid 46799980)
30. Chen R, Gandhi V, Plunkett W: A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 66:10959-10966, 2006 (Pubitemid 44876995)
31. Weingrill E, Wolfler A, Strunk D, et al: Roscovitine in B-chronic lymphocytic leukemia cells: High apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status. Haematologica 92:1286-1288, 2007 (Pubitemid 350144200)